



















































131. Cummings Joyner AK, Snider JT, Wade SW, Wang ST, Buessing MG, Johnson S, Gergis U. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. *Adv Ther.* 2022 Aug;39(8):3560-3577. doi: 10.1007/s12325-022-02188-0. Epub 2022 June 11. PMID: 35689726; PMCID: PMC9309131.
132. Hernandez I, Prasad V, Gellad WF. Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. *JAMA Oncol.* 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977. Erratum in: *JAMA Oncol.* 2018 Oct 1;4(10):1439. PMID: 29710129; PMCID: PMC6145722.
133. Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. *J Med Econ.* 2019 Jul;22(7):613-615. doi: 10.1080/13696998.2019.1582059. Epub 2019 March 21. PMID: 30747012.
134. Tong Y, Udupa JK, Chong E, Winchell N, Sun C, Zou Y, Schuster SJ, Torigian DA. Prediction of lymphoma response to CAR T cells by deep learning-based image analysis. *PLoS One.* 2023 Jul 21;18(7):e0282573. doi: 10.1371/journal.pone.0282573. PMID: 37478073; PMCID: PMC10361488.
135. Naghizadeh A, Tsao WC, Hyun Cho J, Xu H, Mohamed M, Li D, Xiong W, Metaxas D, Ramos CA, Li D. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. *PLoS Comput Biol.* 2022 Mar 18;18(3):e1009883. doi: 10.1371/journal.pcbi.1009883. PMID: 35303007; PMCID: PMC8955962.
136. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. *Cancer Discov.* 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2. PMID: 23550147; PMCID: PMC3667586.